Corrigendum: Androgen insensitivity syndrome: preventive gonadectomy, "pros" and "cons" (Obesity and metabolism. 2024;21(1):85-91. doi: https://doi.org/10.14341/omet13024)

A corrigendum on "Androgen insensitivity syndrome: preventive gonadectomy, "pros" and "cons"" (Obesity and metabolism by Еvgenia A. Starostina, Nadezhda V. Frolkova, Seidbike M. Seidova, Elena G. Przhiyalkovskaya, Nadezhda M. Platonova (2024). Obesity and metabolism. 2024;21(1):85-91. doi: https://doi.org/10.14341/omet13024

On page 87 the sentence “In addition, testosterone preparations are used to treat infertility in patients with a mild form of STF [3]” was removed. Added paragraph “Birnbaum W et al. conducted a multicenter, double-blind, randomized, crossover study in three university medical centers and three specialized hospitals in Germany. In this study, patients aged 18-54 years with karyotype 46,XY, genetically confirmed CAIS, removed gonads, were treated with either estradiol drugs at a dose of 1.5 mg/day for 6 months, followed by a transition to testosterone 50 mg /day for 6 months (sequence A), or testosterone preparations 50 mg/day for 6 months, followed by a transition to estradiol 1.5 mg/day for 6 months (sequence B).

In the study, testosterone was well tolerated and as safe as estrogen. The authors suggested that testosterone may be an ­alternative replacement therapy for CAIS, particularly for patients with reduced sexual function."

A new source has been added in the reference list section under No. 30: “Birnbaum W, Marshall L, Werner R, et al. Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomized, double-dummy, double-blind crossover trial. Lancet Diabetes Endocrinol. 2018;6(10):771-780. doi:10.1016/S2213-8587(18)30197-9.”

The authors regret the error. The original version of the article has been replaced.